Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

TG-interacting factor 1 (Tgif1)-deficiency attenuates bone remodeling and blunts the anabolic response to parathyroid hormone.

Saito H, Gasser A, Bolamperti S, Maeda M, Matthies L, Jähn K, Long CL, Schlüter H, Kwiatkowski M, Saini V, Pajevic PD, Bellido T, van Wijnen AJ, Mohammad KS, Guise TA, Taipaleenmäki H, Hesse E.

Nat Commun. 2019 Mar 22;10(1):1354. doi: 10.1038/s41467-019-08778-x.

2.

Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity.

Pagnotti GM, Styner M, Uzer G, Patel VS, Wright LE, Ness KK, Guise TA, Rubin J, Rubin CT.

Nat Rev Endocrinol. 2019 Jun;15(6):339-355. doi: 10.1038/s41574-019-0170-1. Review.

3.

A "Connexin" Responsible for the Fatal Attraction of Cancer to Bone.

Waning DL, Guise TA, Mohammad KS.

Cell Metab. 2019 Jan 8;29(1):6-8. doi: 10.1016/j.cmet.2018.12.014.

4.

Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker.

Heinrich D, Bruland Ø, Guise TA, Suzuki H, Sartor O.

Future Oncol. 2018 Oct;14(24):2543-2556. doi: 10.2217/fon-2018-0087. Epub 2018 Jun 21. Review.

5.

Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model.

Regan JN, Mikesell C, Reiken S, Xu H, Marks AR, Mohammad KS, Guise TA, Waning DL.

Front Endocrinol (Lausanne). 2017 Dec 19;8:358. doi: 10.3389/fendo.2017.00358. eCollection 2017.

6.

Breaking Down Barriers to Chemoresistance: Role of Chemotherapy-Induced Osteoblastic Jagged1.

Mohammad KS, Guise TA.

Cancer Cell. 2017 Dec 11;32(6):717-718. doi: 10.1016/j.ccell.2017.11.016.

7.

Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis.

Juárez P, Fournier PGJ, Mohammad KS, McKenna RC, Davis HW, Peng XH, Niewolna M, Mauviel A, Chirgwin JM, Guise TA.

Oncotarget. 2017 Sep 23;8(49):86447-86462. doi: 10.18632/oncotarget.21200. eCollection 2017 Oct 17.

8.

Neuropeptide Y regulates a vascular gateway for hematopoietic stem and progenitor cells.

Singh P, Hoggatt J, Kamocka MM, Mohammad KS, Saunders MR, Li H, Speth J, Carlesso N, Guise TA, Pelus LM.

J Clin Invest. 2017 Dec 1;127(12):4527-4540. doi: 10.1172/JCI94687. Epub 2017 Nov 13.

9.

Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases.

Ross MH, Esser AK, Fox GC, Schmieder AH, Yang X, Hu G, Pan D, Su X, Xu Y, Novack DV, Walsh T, Colditz GA, Lukaszewicz GH, Cordell E, Novack J, Fitzpatrick JAJ, Waning DL, Mohammad KS, Guise TA, Lanza GM, Weilbaecher KN.

Cancer Res. 2017 Nov 15;77(22):6299-6312. doi: 10.1158/0008-5472.CAN-17-1225. Epub 2017 Aug 30.

10.

The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm.

Trivedi T, Zheng Y, Fournier PGJ, Murthy S, John S, Schillo S, Dunstan CR, Mohammad KS, Zhou H, Seibel MJ, Guise TA.

Oncotarget. 2017 Apr 18;8(16):26687-26701. doi: 10.18632/oncotarget.15803.

11.

The Role of TGFβ in Bone-Muscle Crosstalk.

Regan JN, Trivedi T, Guise TA, Waning DL.

Curr Osteoporos Rep. 2017 Feb;15(1):18-23. doi: 10.1007/s11914-017-0344-5. Review.

12.

Differential Bone Loss in Mouse Models of Colon Cancer Cachexia.

Bonetto A, Kays JK, Parker VA, Matthews RR, Barreto R, Puppa MJ, Kang KS, Carson JA, Guise TA, Mohammad KS, Robling AG, Couch ME, Koniaris LG, Zimmers TA.

Front Physiol. 2017 Jan 11;7:679. doi: 10.3389/fphys.2016.00679. eCollection 2016.

13.

Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.

Wright LE, Harhash AA, Kozlow WM, Waning DL, Regan JN, She Y, John SK, Murthy S, Niewolna M, Marks AR, Mohammad KS, Guise TA.

Oncotarget. 2017 Jan 31;8(5):8406-8419. doi: 10.18632/oncotarget.14139.

14.

Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in Mice.

Zhang P, Xing C, Rhodes SD, He Y, Deng K, Li Z, He F, Zhu C, Nguyen L, Zhou Y, Chen S, Mohammad KS, Guise TA, Abdel-Wahab O, Xu M, Wang QF, Yang FC.

Stem Cell Reports. 2016 Jun 14;6(6):914-925. doi: 10.1016/j.stemcr.2016.04.013. Epub 2016 May 26.

15.

Hypercalcemia of Malignancy: A New Twist on an Old Problem.

Mohammad KS, Guise TA.

J Oncol Pract. 2016 May;12(5):435-6. doi: 10.1200/JOP.2016.012062. No abstract available.

PMID:
27170692
16.

Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling.

Regan JN, Waning DL, Guise TA.

Semin Cell Dev Biol. 2016 Jan;49:24-9. doi: 10.1016/j.semcdb.2015.11.007. Epub 2015 Nov 24. Review.

17.

Calcium release channel RyR2 regulates insulin release and glucose homeostasis.

Santulli G, Pagano G, Sardu C, Xie W, Reiken S, D'Ascia SL, Cannone M, Marziliano N, Trimarco B, Guise TA, Lacampagne A, Marks AR.

J Clin Invest. 2015 Nov 2;125(11):4316. doi: 10.1172/JCI84937. Epub 2015 Nov 2. No abstract available.

18.

Excess TGF-β mediates muscle weakness associated with bone metastases in mice.

Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, Chiechi A, Wright LE, Umanskaya A, Niewolna M, Trivedi T, Charkhzarrin S, Khatiwada P, Wronska A, Haynes A, Benassi MS, Witzmann FA, Zhen G, Wang X, Cao X, Roodman GD, Marks AR, Guise TA.

Nat Med. 2015 Nov;21(11):1262-1271. doi: 10.1038/nm.3961. Epub 2015 Oct 12.

19.

Elevated incidence of fractures in women with invasive breast cancer.

Edwards BJ, Gradishar WJ, Smith ME, Pacheco JA, Holbrook J, McKoy JM, Nardone B, Tica S, Godinez-Puig V, Rademaker AW, Helenowski IB, Bunta AD, Stern PH, Rosen ST, West DP, Guise TA.

Osteoporos Int. 2016 Feb;27(2):499-507. doi: 10.1007/s00198-015-3246-3. Epub 2015 Aug 21.

PMID:
26294292
20.

TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis.

Stayrook KR, Mack JK, Cerabona D, Edwards DF, Bui HH, Niewolna M, Fournier PG, Mohammad KS, Waning DL, Guise TA.

Bonekey Rep. 2015 Jul 8;4:719. doi: 10.1038/bonekey.2015.88. eCollection 2015.

21.

Corrigendum: Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin.

Wu C, Rankin EB, Castellini L, Alcudia JF, LaGory EL, Andersen R, Rhodes SD, Wilson TL, Mohammad KS, Castillo AB, Guise TA, Schipani E, Giaccia AJ.

Genes Dev. 2015 Jun 1;29(11):1202. No abstract available.

22.

Cancer-associated muscle weakness: What's bone got to do with it?

Waning DL, Guise TA.

Bonekey Rep. 2015 May 20;4:691. doi: 10.1038/bonekey.2015.59. eCollection 2015. Review.

23.

The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone.

Fournier PG, Juárez P, Jiang G, Clines GA, Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, Wells CD, Chirgwin JM, Guise TA.

Cancer Cell. 2015 Jun 8;27(6):809-21. doi: 10.1016/j.ccell.2015.04.009. Epub 2015 May 14.

24.

Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.

Rhodes SD, Yang H, Dong R, Menon K, He Y, Li Z, Chen S, Staser KW, Jiang L, Wu X, Yang X, Peng X, Mohammad KS, Guise TA, Xu M, Yang FC.

J Bone Miner Res. 2015 Oct;30(10):1840-51. doi: 10.1002/jbmr.2538. Epub 2015 May 21.

25.

Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin.

Wu C, Rankin EB, Castellini L, Alcudia JF, LaGory EL, Andersen R, Rhodes SD, Wilson TL, Mohammad KS, Castillo AB, Guise TA, Schipani E, Giaccia AJ.

Genes Dev. 2015 Apr 15;29(8):817-31. doi: 10.1101/gad.255000.114. Epub 2015 Apr 6. Erratum in: Genes Dev. 2015 Jun 1;29(11):1202. Fernandez-Alcudia, Javier [corrected to Alcudia, Javier F].

26.

Calcium release channel RyR2 regulates insulin release and glucose homeostasis.

Santulli G, Pagano G, Sardu C, Xie W, Reiken S, D'Ascia SL, Cannone M, Marziliano N, Trimarco B, Guise TA, Lacampagne A, Marks AR.

J Clin Invest. 2015 May;125(5):1968-78. doi: 10.1172/JCI79273. Epub 2015 Apr 6. Erratum in: J Clin Invest. 2015 Nov 2;125(11):4316.

27.

Dystrophic spinal deformities in a neurofibromatosis type 1 murine model.

Rhodes SD, Zhang W, Yang D, Yang H, Chen S, Wu X, Li X, Yang X, Mohammad KS, Guise TA, Bergner AL, Stevenson DA, Yang FC.

PLoS One. 2015 Mar 18;10(3):e0119093. doi: 10.1371/journal.pone.0119093. eCollection 2015.

28.

Single-Limb Irradiation Induces Local and Systemic Bone Loss in a Murine Model.

Wright LE, Buijs JT, Kim HS, Coats LE, Scheidler AM, John SK, She Y, Murthy S, Ma N, Chin-Sinex HJ, Bellido TM, Bateman TA, Mendonca MS, Mohammad KS, Guise TA.

J Bone Miner Res. 2015 Jul;30(7):1268-79. doi: 10.1002/jbmr.2458. Epub 2015 Jun 8.

29.

Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis.

Siclari VA, Mohammad KS, Tompkins DR, Davis H, McKenna CR, Peng X, Wessner LL, Niewolna M, Guise TA, Suvannasankha A, Chirgwin JM.

Breast Cancer Res. 2014 Dec 2;16(6):458. doi: 10.1186/s13058-014-0458-y.

30.

Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase.

Buijs JT, Matula KM, Cheung H, Kruithof-de Julio M, van der Mark MH, Snoeks TJ, Cohen R, Corver WE, Mohammad KS, Jonkers J, Guise TA, van der Pluijm G.

J Pathol. 2015 Apr;235(5):745-59. doi: 10.1002/path.4488. Epub 2015 Jan 23.

31.

The microenvironment matters: estrogen deficiency fuels cancer bone metastases.

Wright LE, Guise TA.

Clin Cancer Res. 2014 Jun 1;20(11):2817-9. doi: 10.1158/1078-0432.CCR-14-0576. Epub 2014 May 6.

32.

Molecular mechanisms of bone metastasis and associated muscle weakness.

Waning DL, Guise TA.

Clin Cancer Res. 2014 Jun 15;20(12):3071-7. doi: 10.1158/1078-0432.CCR-13-1590. Epub 2014 Mar 27. Review.

33.

Role of TGF-β in breast cancer bone metastases.

Chiechi A, Waning DL, Stayrook KR, Buijs JT, Guise TA, Mohammad KS.

Adv Biosci Biotechnol. 2013 Oct 1;4(10C):15-30.

34.

Cancer-associated osteoclast differentiation takes a good look in the miR(NA)ror.

Waning DL, Mohammad KS, Guise TA.

Cancer Cell. 2013 Oct 14;24(4):407-9. doi: 10.1016/j.ccr.2013.10.001.

35.

Breast cancer bone metastases: it's all about the neighborhood.

Guise TA.

Cell. 2013 Aug 29;154(5):957-959. doi: 10.1016/j.cell.2013.08.020.

36.

Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.

Rhodes SD, Wu X, He Y, Chen S, Yang H, Staser KW, Wang J, Zhang P, Jiang C, Yokota H, Dong R, Peng X, Yang X, Murthy S, Azhar M, Mohammad KS, Xu M, Guise TA, Yang FC.

J Bone Miner Res. 2013 Dec;28(12):2476-89. doi: 10.1002/jbmr.1992.

37.

RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro.

Casimiro S, Mohammad KS, Pires R, Tato-Costa J, Alho I, Teixeira R, Carvalho A, Ribeiro S, Lipton A, Guise TA, Costa L.

PLoS One. 2013 May 16;8(5):e63153. doi: 10.1371/journal.pone.0063153. Print 2013.

38.

Differential stem- and progenitor-cell trafficking by prostaglandin E2.

Hoggatt J, Mohammad KS, Singh P, Hoggatt AF, Chitteti BR, Speth JM, Hu P, Poteat BA, Stilger KN, Ferraro F, Silberstein L, Wong FK, Farag SS, Czader M, Milne GL, Breyer RM, Serezani CH, Scadden DT, Guise TA, Srour EF, Pelus LM.

Nature. 2013 Mar 21;495(7441):365-9. doi: 10.1038/nature11929. Epub 2013 Mar 13.

39.

Curcuminoids block TGF-β signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis.

Wright LE, Frye JB, Lukefahr AL, Timmermann BN, Mohammad KS, Guise TA, Funk JL.

J Nat Prod. 2013 Mar 22;76(3):316-21. doi: 10.1021/np300663v. Epub 2012 Nov 12.

40.

c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions.

He Y, Rhodes SD, Chen S, Wu X, Yuan J, Yang X, Jiang L, Li X, Takahashi N, Xu M, Mohammad KS, Guise TA, Yang FC.

PLoS One. 2012;7(11):e46900. doi: 10.1371/journal.pone.0046900. Epub 2012 Nov 7.

41.

Halofuginone inhibits the establishment and progression of melanoma bone metastases.

Juárez P, Mohammad KS, Yin JJ, Fournier PG, McKenna RC, Davis HW, Peng XH, Niewolna M, Javelaud D, Chirgwin JM, Mauviel A, Guise TA.

Cancer Res. 2012 Dec 1;72(23):6247-56. doi: 10.1158/0008-5472.CAN-12-1444. Epub 2012 Sep 20.

42.

Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis.

Pollari S, Käkönen RS, Mohammad KS, Rissanen JP, Halleen JM, Wärri A, Nissinen L, Pihlavisto M, Marjamäki A, Perälä M, Guise TA, Kallioniemi O, Käkönen SM.

Mol Cancer Res. 2012 May;10(5):597-604. doi: 10.1158/1541-7786.MCR-11-0482. Epub 2012 Apr 20.

43.

Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?

Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Guise TA, Lipton A, Aapro MS.

Cancer Treat Rev. 2012 Oct;38(6):798-806. doi: 10.1016/j.ctrv.2012.02.008. Epub 2012 Mar 18. Review.

PMID:
22429722
44.

Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad.

Nickerson NK, Mohammad KS, Gilmore JL, Crismore E, Bruzzaniti A, Guise TA, Foley J.

PLoS One. 2012;7(1):e30255. doi: 10.1371/journal.pone.0030255. Epub 2012 Jan 19.

45.

The role of TGF-β in bone metastasis: novel therapeutic perspectives.

Buijs JT, Stayrook KR, Guise TA.

Bonekey Rep. 2012 Jun 6;1:96. doi: 10.1038/bonekey.2012.96. eCollection 2012.

46.

The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.

Wu X, Chen S, He Y, Rhodes SD, Mohammad KS, Li X, Yang X, Jiang L, Nalepa G, Snider P, Robling AG, Clapp DW, Conway SJ, Guise TA, Yang FC.

PLoS One. 2011;6(9):e24917. doi: 10.1371/journal.pone.0024917. Epub 2011 Sep 29.

47.

TGF-β/SMAD/GLI2 signaling axis in cancer progression and metastasis.

Javelaud D, Alexaki VI, Dennler S, Mohammad KS, Guise TA, Mauviel A.

Cancer Res. 2011 Sep 1;71(17):5606-10. doi: 10.1158/0008-5472.CAN-11-1194. Epub 2011 Aug 23. Review.

48.

TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases.

Buijs JT, Stayrook KR, Guise TA.

Cancer Microenviron. 2011 Dec;4(3):261-81. doi: 10.1007/s12307-011-0075-6. Epub 2011 Jul 12.

49.

Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor.

Clines GA, Mohammad KS, Grunda JM, Clines KL, Niewolna M, McKenna CR, McKibbin CR, Yanagisawa M, Suva LJ, Chirgwin JM, Guise TA.

J Bone Miner Res. 2011 Oct;26(10):2523-36. doi: 10.1002/jbmr.450.

50.

Therapeutic strategies to target TGF-β in the treatment of bone metastases.

Buijs JT, Juárez P, Guise TA.

Curr Pharm Biotechnol. 2011 Dec;12(12):2121-37. Review.

PMID:
21619539

Supplemental Content

Loading ...
Support Center